Literature DB >> 29805673

Anesthetic drug propofol inhibits the expression of interleukin-6, interleukin-8 and cyclooxygenase-2, a potential mechanism for propofol in suppressing tumor development and metastasis.

Xuefeng Li1, Longyun Li1, Feng Liang1, Guifeng Liu2, Guoqing Zhao1.   

Abstract

Previous studies have indicated that anesthesia-associated drugs may directly inhibit cellular immunity and humoral immunity, which may be associated with tumor recurrence. The present study demonstrated that propofol may suppress the proliferation of MCF-7 cells and inhibit the expression of interleukin (IL)-6 and IL-8. Subsequent to treatment with propofol, MCF-7 cells demonstrated downregulated cyclooxygenase-2 (COX-2) protein expression and decreased levels of vascular endothelial growth factor and prostaglandin E2 in the supernatant. Therefore, the mechanism of propofol in suppressing tumor development and metastasis may be associated with the inhibition of IL-6, IL-8 and COX-2.

Entities:  

Keywords:  anesthesia drug; antitumor mechanism; cyclooxygenase-2; interleukin-6; interleukin-8; propofol

Year:  2018        PMID: 29805673      PMCID: PMC5958752          DOI: 10.3892/ol.2018.8515

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  36 in total

1.  GABA-receptor agonist, propofol inhibits invasion of colon carcinoma cells.

Authors:  Yufeng Miao; Youwei Zhang; Haijun Wan; Longbang Chen; Fangyu Wang
Journal:  Biomed Pharmacother       Date:  2010-05-04       Impact factor: 6.529

2.  Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer.

Authors:  Balraj Singh; Jacob A Berry; Laura E Vincent; Anthony Lucci
Journal:  J Surg Res       Date:  2006-05-06       Impact factor: 2.192

3.  Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression.

Authors:  Sung-Hee Chang; Catherine H Liu; Rebecca Conway; David K Han; Kasem Nithipatikom; Ovidiu C Trifan; Timothy F Lane; Timothy Hla
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-19       Impact factor: 11.205

4.  Cyclooxygenase-2 is essential for HER2/neu to suppress N- (4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cells.

Authors:  Ann-Marie Simeone; Yu-Jiang Li; Lyle D Broemeling; Marcella M Johnson; Musaffe Tuna; Ana M Tari
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701

5.  Enhancement of antitumor immunity after propofol treatment in mice.

Authors:  Atsuko Kushida; Takefumi Inada; Koh Shingu
Journal:  Immunopharmacol Immunotoxicol       Date:  2007       Impact factor: 2.730

6.  Cyclooxygenase-2 inhibitors demonstrate anti-proliferative effects in oesophageal cancer cells by prostaglandin E(2)-independent mechanisms.

Authors:  B M Deasy; G O'Sullivan-Coyne; T R O'Donovan; S L McKenna; G C O'Sullivan
Journal:  Cancer Lett       Date:  2007-08-17       Impact factor: 8.679

7.  Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer.

Authors:  Young-Eun Joo; Jong-Sun Rew; Young-Ho Seo; Sung-Kyu Choi; Young-Jin Kim; Chang-Soo Park; Sei-Jong Kim
Journal:  J Clin Gastroenterol       Date:  2003-07       Impact factor: 3.062

8.  Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression.

Authors:  L Holmgren; M S O'Reilly; J Folkman
Journal:  Nat Med       Date:  1995-02       Impact factor: 53.440

9.  Induction and mechanism of apoptotic cell death by propofol in HL-60 cells.

Authors:  M Tsuchiya; A Asada; K Arita; T Utsumi; T Yoshida; E F Sato; K Utsumi; M Inoue
Journal:  Acta Anaesthesiol Scand       Date:  2002-10       Impact factor: 2.105

10.  Interleukin-6 gene amplification and shortened survival in glioblastoma patients.

Authors:  A Tchirkov; T Khalil; E Chautard; K Mokhtari; L Véronèse; B Irthum; P Vago; J-L Kémény; P Verrelle
Journal:  Br J Cancer       Date:  2007-01-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.